

PYC Therapeutics Announces Participation in Upcoming U.S. Investor Conferences

PERTH, Australia and SAN DIEGO, Calif. – August 3, 2021 – PYC Therapeutics (ASX: PYC), a biotechnology company combining two complementary platform technologies (selective drug delivery and precision drug design) to develop a new generation of RNA therapeutics to change the lives of patients with inherited diseases, today announced that members of the management team will participate in the following high-profile healthcare investor conferences hosted by U.S. banks:

Wedbush PacGrow Healthcare Conference 2021

Date: Wednesday, August 11

Time: 8:00-8:30 a.m. ET

Panel: Only Have Eyes For You – Ophthalmic Gene Therapy

Canaccord Genuity 41st Annual Growth Conference

Date: Thursday, August 12

Time: 11:30-11:55 a.m. ET

Format: Podium presentation

H.C. Wainwright 2021 Virtual Ophthalmology Investor Conference

Date: Tuesday, August 17

Time: 7:00-7:30 a.m. ET

Format: Podium presentation

Live webcast links from the Wedbush, Canaccord, and H.C. Wainwright conferences will be available in the "Events" section of the Investor & Media Center page of the Company's website at <https://pyctx.com/investor-center/>. Replays of the webcasts will be archived on the Company's website following the conferences.

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a development-stage biotechnology company pioneering a new generation of RNA therapeutics that utilize PYC's proprietary library of naturally derived cell penetrating peptides to overcome the major challenges of current genetic medicines. PYC believes its PPMO (Peptide conjugated Phosphorodiamidate Morpholino Oligomer) technology enables a safer and more effective RNA therapeutic to address the underlying drivers of a range of genetic diseases for which no treatment solutions exist today. The Company is leveraging its leading-edge science to develop a pipeline of novel therapies including three preclinical stage programs focused on inherited eye diseases and preclinical discovery efforts focused on neurodegenerative diseases. PYC's discovery and laboratory operations are located in Australia, and the Company's preclinical, clinical, regulatory and corporate operations are based in San Diego, California. For more information, visit pyctx.com, or follow us on [LinkedIn](#) and [Twitter](#).

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

This ASX announcement was approved and authorized for release by Sahm Nasser, Director and incoming CEO of PYC in the U.S.

CONTACTS:

INVESTORS

Deborah Elson/Matthew DeYoung
Argot Partners
deborah@argotpartners.com
matthew@argotpartners.com

MEDIA

Leo Vartorella
Argot Partners
leo@argotpartners.com